Emily Jane Woo

3.4k total citations
66 papers, 1.8k citations indexed

About

Emily Jane Woo is a scholar working on Epidemiology, Surgery and Molecular Biology. According to data from OpenAlex, Emily Jane Woo has authored 66 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Epidemiology, 20 papers in Surgery and 18 papers in Molecular Biology. Recurrent topics in Emily Jane Woo's work include SARS-CoV-2 and COVID-19 Research (12 papers), Influenza Virus Research Studies (12 papers) and Peripheral Neuropathies and Disorders (10 papers). Emily Jane Woo is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (12 papers), Influenza Virus Research Studies (12 papers) and Peripheral Neuropathies and Disorders (10 papers). Emily Jane Woo collaborates with scholars based in United States, Norway and Hong Kong. Emily Jane Woo's co-authors include Robert Ball, M. Miles Braun, Taxiarchis Botsis, Pedro L. Moro, Dale R. Burwen, Michael Nguyen, Maria Cano, Robert Peter Aaronson, Penina Haber and Scott K. Winiecki and has published in prestigious journals such as JAMA, Journal of Biological Chemistry and The Journal of Cell Biology.

In The Last Decade

Emily Jane Woo

65 papers receiving 1.7k citations

Peers

Countries citing papers authored by Emily Jane Woo

Since Specialization

Citations

This map shows the geographic impact of Emily Jane Woo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily Jane Woo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily Jane Woo more than expected).

Fields of papers citing papers by Emily Jane Woo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily Jane Woo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily Jane Woo. The network helps show where Emily Jane Woo may publish in the future.

Co-authorship network of co-authors of Emily Jane Woo

This figure shows the co-authorship network connecting the top 25 collaborators of Emily Jane Woo. A scholar is included among the top collaborators of Emily Jane Woo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily Jane Woo. Emily Jane Woo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021–February 2022 2023 ·Vaccine ·Emily Jane Woo, Julianne Gee, Paige Marquez, James Baggs, Winston E. Abara, Michael M. McNeil, Rositsa B. Dimova, John R. Su	8
2	Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States 2023 ·JAMA Network Open ·Winston E. Abara, Julianne Gee, Paige Marquez, (unknown), Tanya R. Myers, (unknown), Jane Baumblatt, Emily Jane Woo, Deborah Thompson, Narayan Nair, John R. Su, Tom T. Shimabukuro, David K. Shay	41
3	Postmarketing safety surveillance of high-dose quadrivalent influenza vaccine: Reports to the Vaccine Adverse Event Reporting System 2022 ·Vaccine ·Emily Jane Woo, Pedro L. Moro	2
4	Postmarketing safety surveillance of quadrivalent recombinant influenza vaccine: Reports to the vaccine adverse event reporting system 2021 ·Vaccine ·Emily Jane Woo, Pedro L. Moro	17
5	Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 – 2019 2020 ·Vaccine ·Pedro L. Moro, Emily Jane Woo, Paige Marquez, Maria Cano	13
6	Using Probabilistic Record Linkage of Structured and Unstructured Data to Identify Duplicate Cases in Spontaneous Adverse Event Reporting Systems 2017 ·Drug Safety ·Kory Kreimeyer, David Menschik, Scott K. Winiecki, (unknown), (unknown), Emily Jane Woo, Meghna Alimchandani, (unknown), Craig Zinderman, Richard A. Forshee, Taxiarchis Botsis	28
7	Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System 2017 ·Vaccine ·Emily Jane Woo, Pedro L. Moro, Maria Cano, Christopher Jankosky	21
8	A new algorithmic approach for the extraction of temporal associations from clinical narratives with an application to medical product safety surveillance reports 2016 ·Journal of Biomedical Informatics ·Wei Wang, Kory Kreimeyer, Emily Jane Woo, Robert Ball, Matthew Foster, Abhishek Pandey, John Scott, Taxiarchis Botsis	22
9	Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990‒2015 2016 ·PLoS neglected tropical diseases ·Pedro L. Moro, Emily Jane Woo, (unknown), Paige Lewis, Brett W. Petersen, Maria Cano	16
10	Adverse Events After MMR or MMRV Vaccine in Infants Under Nine Months Old 2016 ·The Pediatric Infectious Disease Journal ·Emily Jane Woo, Scott K. Winiecki, (unknown), Judy A. Beeler	11
11	Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000–12 2015 ·The Lancet Infectious Diseases ·Shahed Iqbal, Jing Shi, Katherine Seib, Paige Lewis, Pedro L. Moro, Emily Jane Woo, Tom T. Shimabukuro, Walter A. Orenstein	9
12	Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005–June 2013 2014 ·Vaccine ·Penina Haber, Pedro L. Moro, Michael M. McNeil, Paige Lewis, Emily Jane Woo, (unknown), Tom T. Shimabukuro	16
13	Postmarketing safety of biologics and biological devices 2013 ·The Spine Journal ·Emily Jane Woo	8
14	Recombinant human bone morphogenetic protein-2: adverse events reported to the Manufacturer and User Facility Device Experience database 2012 ·The Spine Journal ·Emily Jane Woo	84
15	Text mining for the Vaccine Adverse Event Reporting System: medical text classification using informative feature selection 2011 ·Journal of the American Medical Informatics Association ·Taxiarchis Botsis, Michael Nguyen, Emily Jane Woo, Marianthi Markatou, Robert Ball	91
16	Quantal Regulation and Exocytosis of Platelet Dense-Body Granules 2011 ·Biophysical Journal ·Shencheng Ge, Emily Jane Woo, Christy L. Haynes	13
17	SAFETY OF A FIFTH DOSE OF DIPHTHERIA AND TETANUS TOXOID AND ACELLULAR PERTUSSIS VACCINE IN CHILDREN EXPERIENCING EXTENSIVE, LOCAL REACTIONS TO THE FOURTH DOSE 2008 ·The Pediatric Infectious Disease Journal ·Margaret B. Rennels, Steven Black, Emily Jane Woo, Scott R. Campbell, Kathryn M. Edwards	18
18	Effects of Stratification on Data Mining in the US Vaccine Adverse Event Reporting System (VAERS) 2008 ·Drug Safety ·Emily Jane Woo, Robert Ball, Dale R. Burwen, M. Miles Braun	41
19	Comparing data mining methods on the VAERS database 2005 ·Pharmacoepidemiology and Drug Safety ·David Banks, Emily Jane Woo, Dale R. Burwen, (unknown), M. Miles Braun, Robert Ball	65
20	Differential Regulation of Insulin-like Growth Factor-I (IGF-I) Receptor Gene Expression by IGF-I and Basic Fibroblastic Growth Factor 1997 ·Journal of Biological Chemistry ·Catalina Hernández‐Sánchez, Haim Werner, Charles T. Roberts, Emily Jane Woo, Dean W. Hum, Stephen M. Rosenthal, Derek LeRoith	78

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact